Lupin Launches Generic Drugs in US: USFDA Approval
By Rediff Money Desk, New Delhi Jun 03, 2024 17:11
Lupin has received USFDA approval to launch generic Doxycycline for Injection and Letermovir Tablets in the US market, targeting a combined annual market value of USD 362 million.

New Delhi, Jun 3 (PTI) Drug maker Lupin on Monday said it has launched a generic medication used to treat or prevent bacterial infections in the US market.
The company has launched Doxycycline for Injection USP (100 single-dose vial) in the US post approvals from the US Food and Drug Administration (USFDA), the Mumbai-based drug maker said in a statement.
The company's product is a generic equivalent of Pfizer Inc's Vibramycin for Injection which is indicated to reduce the development of drug-resistant bacteria.
As per the IQVIA MAT April 2024 data, Doxycycline for Injection USP had an estimated annual sale of USD 48 million in the US.
Lupin said it has also received tentative approval from the USFDA for its abbreviated new drug application for Letermovir Tablets, 240 mg and 480 mg.
The product is the generic equivalent of Merck Sharp & Dohme LLC's Prevymis tablets (240 mg and 480 mg).
Letermovir tablets are indicated to prevent disease caused by a virus called cytomegalovirus (CMV).
As per the IQVIA MAT April 2024 data, Letermovir tablets had an estimated annual sale of USD 314 million in the US.
Shares of the company on Monday ended 0.25 per cent at Rs 1,583.95 apiece on the BSE.
The company has launched Doxycycline for Injection USP (100 single-dose vial) in the US post approvals from the US Food and Drug Administration (USFDA), the Mumbai-based drug maker said in a statement.
The company's product is a generic equivalent of Pfizer Inc's Vibramycin for Injection which is indicated to reduce the development of drug-resistant bacteria.
As per the IQVIA MAT April 2024 data, Doxycycline for Injection USP had an estimated annual sale of USD 48 million in the US.
Lupin said it has also received tentative approval from the USFDA for its abbreviated new drug application for Letermovir Tablets, 240 mg and 480 mg.
The product is the generic equivalent of Merck Sharp & Dohme LLC's Prevymis tablets (240 mg and 480 mg).
Letermovir tablets are indicated to prevent disease caused by a virus called cytomegalovirus (CMV).
As per the IQVIA MAT April 2024 data, Letermovir tablets had an estimated annual sale of USD 314 million in the US.
Shares of the company on Monday ended 0.25 per cent at Rs 1,583.95 apiece on the BSE.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 8.41 ( -4.65)
- 67528712
- Quadrant Televenture
- 0.48 ( -4.00)
- 25331824
- GTL Infrastructure
- 1.73 ( 0.00)
- 22518929
- Srestha Finvest
- 0.64 ( -3.03)
- 20152471
- Murae Organisor
- 1.94 ( 0.00)
- 14675141
MORE NEWS

Nirani Sugars to Build Rs 2,000 Cr Chemical...
Nirani Sugars has partnered with the Karnataka government to build a Polylactic Acid...

French Firm Signs LNG Supply Deal with GSPC, India
TotalEnergies signs a 10-year deal to supply 400,000 tonnes of LNG per year to GSPC,...

Prostarm Info Systems IPO Approved by Sebi
Prostarm Info Systems, a power solutions company, has received Sebi's approval to...